Literature DB >> 36190569

The inflammatory response and blood-spinal cord barrier integrity in traumatic spinal cord injury: a prospective pilot study.

Thea Overgaard Wichmann1, Helge Kasch2,3, Stig Dyrskog4, Kristian Høy3,5, Bjarne Kuno Møller6, Jan Krog7, Claus Vinter Bødker Hviid8,9, Hans Jürgen Hoffmann3,10, Mikkel Mylius Rasmussen11,3.   

Abstract

PURPOSE: Triggering of inflammatory responses and disruption of blood-spinal cord barrier (BSCB) integrity are considered pivotal events in the pathophysiology of traumatic spinal cord injury (TSCI). Yet, these events are poorly understood and described in humans. This study aims to describe inflammatory responses and BSCB integrity in human TSCI.
METHODS: Fifteen TSCI patients and fifteen non-TSCI patients were prospectively recruited from Aarhus University Hospital, Denmark. Peripheral blood (PB) and cerebrospinal fluid (CSF) were collected at median day 0 [IQR: 1], median day 9 [IQR: 2], and median day 148 [IQR: 49] after injury. PB and CSF were analyzed for immune cells by flow cytometry, cytokines by multiplex immunoassay, and BSCB integrity by IgG Index.
RESULTS: Eleven TSCI patients completed follow-up. Results showed alterations in innate and adaptive immune cell counts over time. TSCI patients had significantly increased cytokine concentrations in CSF at the first and second follow-up, while only concentrations of interleukin (IL)-4, IL-8, and tumor necrosis factor-α remained significantly increased at the third follow-up. In PB, TSCI patients had significantly increased IL-6, IL-8, and IL-10 concentrations and significantly decreased interferon-γ concentrations at the first follow-up. Results further showed increased IgG Index indicative of BSCB disruption in seven TSCI patients at the first follow-up, five TSCI patients at the second follow-up, and two patients at the third follow-up.
CONCLUSIONS: Our results suggest that TSCI mainly triggers innate inflammatory responses that resolves over time, although with some degree of non-resolving inflammation, particularly in CSF. Our results cannot confirm BSCB disruption in all TSCI patients.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.

Entities:  

Keywords:  Blood-spinal cord barrier; Flow cytometry; Imaging flow cytometry; Inflammation; Multiplex immunoassay; Traumatic spinal cord injury

Year:  2022        PMID: 36190569     DOI: 10.1007/s00701-022-05369-6

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.816


  32 in total

Review 1.  The blood-spinal cord barrier: morphology and clinical implications.

Authors:  Viktor Bartanusz; Daniela Jezova; Betty Alajajian; Murat Digicaylioglu
Journal:  Ann Neurol       Date:  2011-06-14       Impact factor: 10.422

2.  Predicting Injury Severity and Neurological Recovery after Acute Cervical Spinal Cord Injury: A Comparison of Cerebrospinal Fluid and Magnetic Resonance Imaging Biomarkers.

Authors:  Turker Dalkilic; Nader Fallah; Vanessa K Noonan; Sanam Salimi Elizei; Kevin Dong; Lise Belanger; Leanna Ritchie; Angela Tsang; Etienne Bourassa-Moreau; Manraj K S Heran; Scott J Paquette; Tamir Ailon; Nicolas Dea; John Street; Charles G Fisher; Marcel F Dvorak; Brian K Kwon
Journal:  J Neurotrauma       Date:  2017-11-06       Impact factor: 5.269

3.  Possible Strategies to Optimize a Biomarker Discovery Approach to Correlate with Neurological Outcome in Patients with Spinal Cord Injury: A Pilot Study.

Authors:  Mercedes Fernández; Vito Antonio Baldassarro; Rita Capirossi; Roberto Montevecchi; Jacopo Bonavita; Maura Cescatti; Tiziana Giovannini; Giulia Giovannini; Mariella Uneddu; Gordini Giovanni; Luciana Giardino; Laura Calzà
Journal:  J Neurotrauma       Date:  2019-08-01       Impact factor: 5.269

Review 4.  Human immune system variation.

Authors:  Petter Brodin; Mark M Davis
Journal:  Nat Rev Immunol       Date:  2016-12-05       Impact factor: 53.106

5.  Cerebrospinal Fluid Biomarkers in Human Spinal Cord Injury from a Phase II Minocycline Trial.

Authors:  Steve Casha; Tiffany Rice; David P Stirling; Claudia Silva; Sharmilee Gnanapavan; Gavin Giovannoni; R John Hurlbert; V Wee Yong
Journal:  J Neurotrauma       Date:  2018-08-15       Impact factor: 5.269

6.  The cellular inflammatory response in human spinal cords after injury.

Authors:  Jennifer C Fleming; Michael D Norenberg; David A Ramsay; Gregory A Dekaban; Alexander E Marcillo; Alvaro D Saenz; Melissa Pasquale-Styles; W Dalton Dietrich; Lynne C Weaver
Journal:  Brain       Date:  2006-10-28       Impact factor: 13.501

7.  A pilot study on temporal changes in IL-1β and TNF-α serum levels after spinal cord injury: the serum level of TNF-α in acute SCI patients as a possible marker for neurological remission.

Authors:  B Biglari; T Swing; C Child; A Büchler; F Westhauser; T Bruckner; T Ferbert; H Jürgen Gerner; A Moghaddam
Journal:  Spinal Cord       Date:  2015-03-10       Impact factor: 2.772

8.  Clinical correlates of elevated serum concentrations of cytokines and autoantibodies in patients with spinal cord injury.

Authors:  Andrew L Davies; Keith C Hayes; Gregory A Dekaban
Journal:  Arch Phys Med Rehabil       Date:  2007-11       Impact factor: 3.966

Review 9.  The translational importance of establishing biomarkers of human spinal cord injury.

Authors:  Sanam Salimi Elizei; Brian K Kwon
Journal:  Neural Regen Res       Date:  2017-03       Impact factor: 5.135

10.  Neuroprotection of netrin-1 on neurological recovery via Wnt/β-catenin signaling pathway after spinal cord injury.

Authors:  Kai Gao; Jianbing Niu; Xiaoqian Dang
Journal:  Neuroreport       Date:  2020-05-07       Impact factor: 1.703

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.